STRATEC Biomedical AG
STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. T… Read more
STRATEC Biomedical AG (SRBZF) - Net Assets
Latest net assets as of September 2024: $227.76 Million USD
Based on the latest financial reports, STRATEC Biomedical AG (SRBZF) has net assets worth $227.76 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($450.84 Million) and total liabilities ($223.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $227.76 Million |
| % of Total Assets | 50.52% |
| Annual Growth Rate | 8.49% |
| 5-Year Change | 47.83% |
| 10-Year Change | N/A |
| Growth Volatility | 4.76 |
STRATEC Biomedical AG - Net Assets Trend (2014–2023)
This chart illustrates how STRATEC Biomedical AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for STRATEC Biomedical AG (2014–2023)
The table below shows the annual net assets of STRATEC Biomedical AG from 2014 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $233.33 Million | +3.62% |
| 2022-12-31 | $225.18 Million | +9.44% |
| 2021-12-31 | $205.76 Million | +19.25% |
| 2020-12-31 | $172.54 Million | +9.32% |
| 2017-12-31 | $157.84 Million | +10.89% |
| 2016-12-31 | $142.34 Million | +9.26% |
| 2015-12-31 | $130.28 Million | +16.27% |
| 2014-12-31 | $112.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to STRATEC Biomedical AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $233.33 Million | 100.00% |
| Total Equity | $233.33 Million | 100.00% |
STRATEC Biomedical AG Competitors by Market Cap
The table below lists competitors of STRATEC Biomedical AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VIA OPTRONICS AG SP.ADS/1
F:5UU1
|
$676.14K |
|
Romcab SA
RO:MCAB
|
$676.62K |
|
AfroCentric Investment Corp
JSE:ACT
|
$677.03K |
|
FORTINET
BE:FO8
|
$677.09K |
|
CTS EVENTIM - Dusseldorf Stock Exchang
DU:EVD
|
$675.70K |
|
CRTMF
OTCQB:CRTMF
|
$674.96K |
|
Reach Energy Bhd
KLSE:5256
|
$674.92K |
|
KATORO GOLD PLC LS-01
F:622
|
$674.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STRATEC Biomedical AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 225,184,000 to 233,326,000, a change of 8,142,000 (3.6%).
- Net income of 13,067,000 contributed positively to equity growth.
- Dividend payments of 11,790,000 reduced retained earnings.
- Other factors increased equity by 6,865,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $13.07 Million | +5.6% |
| Dividends Paid | $11.79 Million | -5.05% |
| Other Changes | $6.87 Million | +2.94% |
| Total Change | $- | 3.62% |
Book Value vs Market Value Analysis
This analysis compares STRATEC Biomedical AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.12x to 3.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $14.26 | $72.96 | x |
| 2021-12-31 | $16.97 | $72.96 | x |
| 2022-12-31 | $18.52 | $72.96 | x |
| 2023-12-31 | $19.19 | $72.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STRATEC Biomedical AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.60%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.99%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.00x
- Recent ROE (5.60%) is below the historical average (14.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 17.64% | 13.65% | 1.05x | 1.23x | $8.56 Million |
| 2015 | 16.95% | 15.03% | 0.92x | 1.22x | $9.06 Million |
| 2016 | 13.70% | 10.54% | 0.72x | 1.81x | $5.26 Million |
| 2017 | 16.24% | 12.22% | 0.80x | 1.67x | $9.85 Million |
| 2020 | 14.59% | 10.07% | 0.75x | 1.92x | $7.92 Million |
| 2021 | 19.42% | 13.91% | 0.78x | 1.79x | $19.38 Million |
| 2022 | 12.98% | 10.64% | 0.69x | 1.77x | $6.70 Million |
| 2023 | 5.60% | 4.99% | 0.56x | 2.00x | $-10.27 Million |
Industry Comparison
This section compares STRATEC Biomedical AG's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $21,282,152,580
- Average return on equity (ROE) among peers: 31.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STRATEC Biomedical AG (SRBZF) | $227.76 Million | 17.64% | 0.98x | $675.78K |
| Arçelik Anonim Sirketi (ACKAF) | $59.56 Billion | 12.87% | 3.33x | $19.95K |
| Argo Group US Inc. 6.5% SR NTS 42 (ARGD) | $1.23 Billion | -15.51% | 0.05x | $232.01K |
| American Crystal Sugar Company PFD REST NON DIV (ASCS) | $316.55 Million | 254.25% | 1.77x | $54.72 Million |
| Autobacs Seven Co. Ltd (ATBSF) | $127.35 Billion | 4.24% | 0.47x | $167.34K |
| Brookfield Asset Management Inc FR PRF PERPETUAL CAD 25 Ser 2 Cls A (BKFAF) | $11.77 Billion | 6.69% | 3.72x | $76.46K |
| Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) | $5.08 Billion | 14.69% | 0.67x | $9.45 Million |
| BOL Bancshares Inc. PFD (BOLBP) | $11.94 Million | 0.62% | 6.68x | $0.91 |
| NYSE LISTED TEST STOCK FOR CTS AND CQS (CBO) | $3.36 Billion | 11.17% | 0.52x | $237.68K |
| Canadian Utilities Limited 2ND PFD SER Y (CNAUF) | $4.14 Billion | 10.45% | 1.28x | $142.90K |
| Central Parking Finance Trust PFD TR CV SECS (CRLKP) | $374.10 | 13.04% | 2.96x | $224.78K |